Elicio Therapeutics, Inc. ELTX
1.61 USD -0.03 (-2.13%)
At closeNov 10, 2026, 4:00 PM EST
1.61 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
1.58 Day range 1.77
1.25 52-week range 16.00
- YTD
- -79.77%
- 1 year
- -81.75%
News
benzinga.com HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Lowers Price Target to $21 HC Wainwright & Co. analyst Robert Burns maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and lowers the price target from $23 to $21.
benzinga.com Elicio Therapeutics Q3 EPS $(0.30) Beats $(0.43) Estimate Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.43) by 30.23 percent. This is a 50 percent increase over losses of…
globenewswire.com Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…
globenewswire.com Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for…
benzinga.com Elicio Therapeutics To Demonstrate Data Of Two Poster Presentations For Its Phase 2 AMPLIFY-7P Trial Of Camupepimut , Expanded Antigen-Agnostic Intratumoral Application Of AMP-Adjuvant Platform At Society For Immunotherapy Of Cancer's Annual Meeting Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that…
benzinga.com Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results At ESMO Congress 2026; Multiple Pre-Specified Subgroup Analyses Favored Camupepimut, Including Patients With And Without Detectable Baseline ctDNA; Encouraging Disease-Free Survival Outcomes Were Observed In Both ctDNA-Negative And ctDNA-Positive Patients Elicio Therapeutics, Inc. (NASDAQ:ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced results
benzinga.com Elicio Therapeutics Presents Data From Its Phase 2 AMPLIFY-7P Trial Of Camupepimut At European Society For Medical Oncology Congress 2026 Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced results
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics…